MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/00365521.2025.2597263

Медицинская библиотека · Scandinavian journal of gastroenterology · 2025

High persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort study.

Šubic Živa, Drobne David, Novak Gregor

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

The number of advanced therapies for inflammatory bowel disease (IBD) has increased in recent years. Ustekinumab, an inhibitor of interleukin -12 and -23, was mostly used for later-line treatment, where its efficacy may be reduced. Recent expiration of its patent and the introduction of affordable biosimilars introduced interest of using ustekinumab earlier as a first-line option. However, data on the effectiveness in the first-line setting remain limited. The aim was to evaluate the efficacy and treatment persistence of ustekinumab when used as a first-line treatment in IBD.

MATERIALS AND

METHODS

This retrospective longitudinal cohortstudy included 71 naïve patients to advanced therapy who initiated first-line treatment with ustekinumab. Data on demographics, patient clinical characteristics, treatment persistence, serum concentrations of ustekinumab, and clinical, biochemical, and endoscopic outcomes, were collected. A Kaplan-Meier curve was performed to assess treatment persistence.

RESULTS

Median follow-up was 20.8 months (interquartile range 11.3-48.5). One-year treatment persistence with ustekinumab was 88%, with a rate of 92% in Crohn's disease (CD), and 82% in ulcerative colitis (UC). Biochemical remission was achieved in 77.6% of patients based on C-reactive protein (≤5 mg/ml) and in 71.1% based on fecal calprotectin (<100 mg/kg). Endoscopic remission (absence of ulcers in CD and endoscopic Mayo ≤1 in UC) was observed in 58.3% of patients.

CONCLUSIONS

First-line treatment with ustekinumab demonstrates high treatment-persistence and is associated with substantial rates of clinical, biochemical, and endoscopic remission in patients with IBD.

Для цитирования: Šubic Živa, Drobne David, Novak Gregor. High persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort study.. Scandinavian journal of gastroenterology. 2025. DOI: 10.1080/00365521.2025.2597263.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.